Aneta Baran

Aneta Baran

Auto-generated profile, based on publicly available information

Aneta Baran

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Cancer Research Communications
Verified
Journal Article
Open access
JMJamie N. Guillen Magaña
Jamie N. Guillen Magaña
MZMarkella Zannikou
Markella Zannikou
ABAneta Baran
Aneta Baran
SSSara Heather Small
Sara Heather Small
MSMichael Schieber
Michael Schieber
Leonidas C PlataniasLeonidas C Platanias
Leonidas C Platanias
We examined the role of SLFN12, a member of the Schlafen (SLFN) family of interferon-regulated genes and proteins in leukemogenesis, and its potential as a therapeutic target in acute myeloid leukemia (AML). We explored the effects of velcrins, a class of small molecules able to modulate SLFN12 biological activity, on AML cells. Velcrin treatment of AML cells stabilized SLFN12 and promoted SLFN12 complex formation with phosphodiesterase 3A or phosphodiesterase 3B. Such effects were associated with growth-inhibitory and proapoptotic responses, as well as potent suppressive effects on leukemic cell growth. In addition, velcrin treatment suppressed clonogenic capacity of primitive leukemic progenitors and significantly extended survival in a mouse AML xenograft model. Taken together, these findings establish an important role of SLFN12 in leukemogenesis and raise the potential for the use of velcrins as a therapeutic strategy for AML. Significance: Our studies identify SLFN12 as a potential target in AML with important clinical–translational implications.

17 November 2025
Verified
Other
Open access
JMJamie N. Guillen Magaña
Jamie N. Guillen Magaña
MZMarkella Zannikou
Markella Zannikou
ABAneta Baran
Aneta Baran
SSSara Heather Small
Sara Heather Small
MSMichael Schieber
Michael Schieber
Leonidas C PlataniasLeonidas C Platanias
Leonidas C Platanias
Figure S3. Stable body weight and tumor volume post-BAY treatment in vivo.

17 November 2025
Verified
Other
Open access
JMJamie N. Guillen Magaña
Jamie N. Guillen Magaña
MZMarkella Zannikou
Markella Zannikou
ABAneta Baran
Aneta Baran
SSSara Heather Small
Sara Heather Small
MSMichael Schieber
Michael Schieber
Leonidas C PlataniasLeonidas C Platanias
Leonidas C Platanias
Effects of velcrin treatment on leukemic progenitor colony formation. A and B, Clonogenic capability of HEL (A) or U937 (B) cells following treatment with increasing concentrations of BAY 2666605, as noted, for 1 week. Leukemic colony formation (CFU-L) was calculated as percent colony formation relative to vehicle control (DMSO)–treated cells (indicated by the dotted line) and means ± SEM of (A) three or (B) five independent experiments are presented. Each dot represents an independent experiment. At each concentration, statistical significance was determined using a one-sample Student t test compared with 100%; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. C, Effects on primary AML-derived leukemic progenitor colony formation. Cells were plated in a methylcellulose culture assay system and treated the same day with BAY 2666605 at the noted concentrations. Leukemic colony formation (CFU-L) was calculated as percent colony formation of BAY 2666605–treated patient samples (2 weeks) relative to vehicle control (DMSO)–treated cells (indicated by the dotted line). Each dot represents an independent experiment. Data are shown as means ± SEM of five independent experiments, as indicated, using primary cells from five different patients with AML. At each concentration, statistical significance was determined using a one-sample Student t test compared with 100%; ***, P ≤ 0.001; ****, P ≤ 0.0001. BAY, BAY 2666605.

17 November 2025
Verified
Other
Open access
JMJamie N. Guillen Magaña
Jamie N. Guillen Magaña
MZMarkella Zannikou
Markella Zannikou
ABAneta Baran
Aneta Baran
SSSara Heather Small
Sara Heather Small
MSMichael Schieber
Michael Schieber
Leonidas C PlataniasLeonidas C Platanias
Leonidas C Platanias
Antileukemic effects of the velcrin–Aza combination. A and B, Cell viability of HEL (A) or U937 (B) cells treated with DMSO (vehicle control) or with increasing concentrations of BAY 2666605 (BAY), Aza, or the combination of BAY 2666605 with Aza as measured by WST-1 cell viability assay. Data are presented as the means ± SEM of three independent experiments, each conducted in triplicate, and are expressed as percent cell viability relative to vehicle control (DMSO)–treated cells. IC50 values for the indicated cell lines were calculated by fitting a nonlinear regression analysis using the “log (inhibitor) vs. response - three parameters” function in GraphPad Prism software (v.10). CI was calculated using Compusyn software, in which CI < 1 is synergistic, CI > 1 is antagonistic, and CI = 1 is additive. C and D, Clonogenic capability of (C) HEL or (D) U937 cells plated in a methylcellulose culture assay system in the presence of BAY 2666605, Aza, or the combination of BAY 2666605 with Aza, relative to vehicle control (DMSO; indicated by the dotted line) at the indicated concentrations. The percent of leukemic colony formation (CFU-L) is shown relative to vehicle control (DMSO)–treated cells and represents mean ± SEM of four independent experiments. Each dot represents an independent experiment. Statistical significance was determined using a one-way ANOVA, followed by a Tukey multiple comparisons test to correct for pairwise comparisons; ns, not significant; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. BAY, BAY 2666605.

17 November 2025
Verified
Other
Open access
JMJamie N. Guillen Magaña
Jamie N. Guillen Magaña
MZMarkella Zannikou
Markella Zannikou
ABAneta Baran
Aneta Baran
SSSara Heather Small
Sara Heather Small
MSMichael Schieber
Michael Schieber
Leonidas C PlataniasLeonidas C Platanias
Leonidas C Platanias
Antileukemic activity of BAY 2666605 in vivo. A, Schematic representation of the experimental approach for the treatment regimen used for the xenograft AML mouse model. B, Tumor volumes (means ± SEM) are shown for mice treated with either vehicle control (5% ethanol with 95% polyethylene glycol-400) or BAY 2666605 (5 mg/kg; n = 10 per group). Pink bars indicate treatment window. Tumor growth from the start of treatment (day 13) until the end of treatment (day 24) was analyzed using a mixed-effects linear regression model. Tumor volume was log-transformed to satisfy the normality assumption. Treatment group, time, and their interaction were included as fixed effects and mice as a random effect. The interaction was statistically significant (P < 0.0001). The P values comparing treatments at each time point were adjusted for multiple comparisons using the Holm–Šídák method; *, P ≤ 0.05. Arrowheads indicate when mice were euthanized because of meeting study endpoints after tumor volume measurement. C, Kaplan–Meier survival analysis for mice treated with BAY 2666605 vs. vehicle control. Mice were compassionately euthanized once tumor volume was ≥2,000 mm3 or weight loss was greater than 20%; ***, P = 0.0004 using a Mantel–Cox (log-rank) test. D, Table summarizing estimated median survival (in days) of mice from each treatment group. BAY, BAY 2666605; SQ, subcutaneous. [A, Created in BioRender. Guillen Magana, J. (2025) https://BioRender.com/yw4tt0f.]

17 November 2025
Verified
Other
Open access
JMJamie N. Guillen Magaña
Jamie N. Guillen Magaña
MZMarkella Zannikou
Markella Zannikou
ABAneta Baran
Aneta Baran
SSSara Heather Small
Sara Heather Small
MSMichael Schieber
Michael Schieber
Leonidas C PlataniasLeonidas C Platanias
Leonidas C Platanias
Effects of velcrin treatment on SLFN12 expression in vivo. A, Schematic representation of the treatment regimen used for the xenograft AML mouse model using BAY 2666605 or vehicle control. B, Tumor growth curves of nude (NU/NU) mice treated and challenged with HEL cells. Each point represents the mean tumor volume ± SEM per group for vehicle control (5% ethanol with 95% polyethylene glycol-400)– and BAY 2666605–treated mice (n = 5 for control; n = 4 for treated). Pink bar indicates days in which mice were treated with BAY 2666605 or vehicle control. Tumor growth from the start of treatment (day 14) until the end of treatment (day 18) was analyzed using a mixed-effects linear regression model. Tumor volume was log-transformed to satisfy the normality assumption. Treatment group, time, and their interaction were included as fixed effects and mice as a random effect. The interaction was statistically significant (P < 0.001). The P value comparing treatments at day 18 is reported (*, P = 0.011). C, Tumor lysates from the experiment shown in panel (B) were subjected to SDS-PAGE and probed for SLFN12 protein expression. D, Tumor samples from the same experiment (n = 4 per group) were subjected to RNA-seq. Volcano plot shows the differentially up- or downregulated genes between the velcrin treatment group and the vehicle control group. Genes deemed statistically significant are highlighted in red. Data are from four biological replicates per group (see also Supplementary Fig. S2). E and F, Gene ontology (GO) analysis of differentially expressed genes that were (E) downregulated or (F) upregulated in mouse tumors treated with BAY 2666605 compared with vehicle control–treated mice. Relevant pathways associated with differentially expressed genes are underlined in red. BAY, BAY 2666605; SQ, subcutaneous. [A, Created in BioRender. Guillen Magana, J. (2025) https://BioRender.com/aqz79jx.]